scorecardresearchBiocon Share Price Live NSE, BSE, Today - Biocon Stock Price
Mintgenie
Asian Paints2,861.00-0.55 (-0.02%)
Axis Bank1,132.304.95 (0.44%)
Bajaj Finance6,755.00-538.90 (-7.39%)
Bajaj Finserv1,601.20-54.60 (-3.30%)
Bharti Airtel1,327.65-8.30 (-0.62%)
HCL Technologies1,526.4522.80 (1.52%)
HDFC Bank1,514.954.30 (0.28%)
Hindustan Unilever2,241.9010.90 (0.49%)
ICICI Bank1,109.95-3.10 (-0.28%)
ITC439.752.25 (0.51%)
Indusind Bank1,466.75-29.40 (-1.97%)
Infosys1,438.00-0.40 (-0.03%)
Kotak Mahindra Bank1,630.90-12.10 (-0.74%)
Larsen & Toubro3,625.80-24.85 (-0.68%)
Mahindra & Mahindra2,073.00-22.55 (-1.08%)
Maruti Suzuki India12,835.00-71.10 (-0.55%)
NTPC357.05-1.25 (-0.35%)
Nestle India2,522.00-40.70 (-1.59%)
Power Grid Corporation Of India295.602.50 (0.85%)
Reliance Industries2,922.003.60 (0.12%)
State Bank Of India804.95-7.65 (-0.94%)
Sun Pharmaceutical Industries1,504.55-16.00 (-1.05%)
Tata Consultancy Services3,859.457.60 (0.20%)
Tata Motors1,004.153.35 (0.33%)
Tata Steel168.150.55 (0.33%)
Tech Mahindra1,298.10108.00 (9.07%)
Titan Company3,576.003.35 (0.09%)
Ultratech Cement9,677.80-5.80 (-0.06%)
Wipro473.4512.45 (2.70%)

Biocon

BSE: 532523 | NSE: BIOCON | ISIN: INE376G01013 | SECTOR: Biotechnology & Drugs

₹301.10 9.40 (3.22%)

26 Apr 2024, 05:57 (IST)

  • Open

    292.00

  • High

    304.55

  • Low

    292.00

  • Prev Close

    291.70

  • P/E

    -

  • Median P/E

    -

  • P/B

    -

  • Median P/B

    -

  • Market Cap

    360.36B

  • Volume

    786.63K

  • Vol. (20 day Avg.)

    0

  • PEG

    -

  • Div.Yield

    -

  • Bid

    301.15

  • Ask

    301.35
View all metrics

Company Description

  • Biotechnology & Drugs

  • BSE

    532523

  • NSE

    BIOCON

  • ISIN

    INE376G01013

Biocon Limited is an India-based biopharmaceutical company, which focuses on treating diabetes, cancer and autoimmune diseases. Its segment includes Generics, Biosimilars, Novel Biologics and Research Services. It has developed and commercialized novel biologics, biosimilars, and complex small molecule active pharmaceutical ingredients (APIs) in India and several key global markets, as well as Generic Formulations in the United Sates, Europe and key emerging markets. Its API portfolio includes cardiology, anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology and other key products. Its products include Tacrolimus, Rosuvastatin, Simvastatin, Atorvastatin, Pravastatin, Fingolimod and others. It has over five facilities across Bangalore, Hyderabad and Visakhapatnam in India. Its API manufacturing facilities leverage complex technology platforms that range from microbial fermentation, chromatographic purification, chemical synthesis, peptide synthesis and HPAPIs.

Company Officers

  • Kiran Mazumdarshaw

    Executive Chairperson of the Board

  • Siddharth Mittal

    Chief Executive Officer, Managing Director, Executive Director

  • Peter Bains

    Group Chief Executive Officer

  • Shreehas Tambe

    Chief Executive Officer, Managing Director

  • Mayank Verma

    Compliance Officer, Company Secretary

  • Maninder Puri

    Head, Human Resources

  • Seema Ahuja

    Global Head - Corporate Brand & Head of Communications - EMs

  • Arun Gupta

    Head, Operations

  • Manoj Pananchukunnath

    Head - Research and Development and Regulatory Sciences

  • Nitin Tiwari

    Head - Quality